Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)

Original languageEnglish
JournalBritish Journal of Dermatology
Volume188
Issue number6
Pages (from-to)793-794
Number of pages2
ISSN0007-0963
DOIs
Publication statusPublished - 24 May 2023

Keywords

  • United States
  • Humans
  • United States Food and Drug Administration
  • Adverse Drug Reaction Reporting Systems
  • Product Surveillance, Postmarketing
  • Stroke/chemically induced
  • Drug-Related Side Effects and Adverse Reactions

Cite this